Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes
Myelodysplastic syndromes and chronic myelomonocytic leukemia are blood disorders characterized by ineffective hematopoiesis and progressive marrow failure that can transform into acute leukemia. The DNA methyltransferase inhibitor 5-azacytidine (AZA) is the most effective pharmacological option, but only ∼50% of patients respond. A response only manifests after many months of treatment and is transient. The reasons underlying AZA resistance are unknown, and few alternatives exist for non-res...Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
(Version of record, pdf, 2.7MB)
- Publisher copy:
- Copyright holder:
- Unnikrishnan et al
- Copyright date:
Copyright © 2017 The Authors.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
If you are the owner of this record, you can report an update to it here: Report update to this record